Antiplatelet Therapy in Chronic Urticaria
Phase 2
Active, not recruiting
- Conditions
- Chronic Urticaria
- Interventions
- Registration Number
- NCT06268470
- Lead Sponsor
- Chulalongkorn University
- Brief Summary
This study compares the combination of antiplatelets and antihistamine versus antihistamine alone for the treatment of chronic spontaneous urticaria
- Detailed Description
This study is a randomized control trial comparing the effectiveness of the combination of antiplatelets and antihistamine and antihistamine alone for the treatment of chronic spontaneous urticaria
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 12
Inclusion Criteria
Chronic spontaneous urticaria
D-dimer levels over 500 ng/ml
Not respond to a conventional dose of antihistamine
Exclusion Criteria
Are taking aspirin
Have bleeding tendency
Have concurrent severe medical illnesses
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Desloratadine plus cilostazol and dipyridamole Desloratadine plus cilostazol and dipyridamole Oral desloratadine 20 mg/day (antihistamine) in conjunction with cilostazol 150 mg/day and dipyridamole 50 mg/day (antiplatelets) for 4 weeks Desloratadine Desloratadine Oral desloratadine 20 mg/day (antihistamine) for 4 weeks Desloratadine plus cilostazol and dipyridamole Desloratadine Oral desloratadine 20 mg/day (antihistamine) in conjunction with cilostazol 150 mg/day and dipyridamole 50 mg/day (antiplatelets) for 4 weeks
- Primary Outcome Measures
Name Time Method Weekly urticaria activity score 4 weeks Urticaria activity score over 7 days (UAS7): scores 0-42 from mild to severe
- Secondary Outcome Measures
Name Time Method D-dimer levels 4 weeks D-dimer levels
Trial Locations
- Locations (1)
Faculty of Medicine, Chulalongkorn University
🇹ðŸ‡Bangkok, Thailand